QuiremSpheres® microspheres, which are based on holmium-166, provide unique imaging capabilities that allow for optimum in vivo dosimetry on a voxel level. This makes it possible to perform post-treatment quantitative verification of the achieved dose distribution, i.e. determining dose-to-tumor and dose-to-tissue. With QuiremSpheres® you treat what you see and see what you treat.
QuiremSpheres® is indicated for the treatment of advanced unresectable liver tumors.
QuiremSpheres® microspheres have the same mode of action as existing Yttrium-90 based SIRT products: the microspheres emit beta radiation that kills tumor cells from close range. In addition, QuiremSpheres® can be visualized with SPECT and MR imaging, even in low concentrations. This is unique and cannot be done with currently available Yttrium-90 based microspheres.
The first and only commercial SIRT solution based on holmium-166.
Based on more than 15 years of technological advancement and clinical research.
Quantitative SPECT and MR imaging properties enable dosimetric treatment verification.
We deliver a complete SIRT solution, for which we have put your convenience as a starting point. This translates into:
QuiremSpheres® is supplied as a standard dose in a single capped V-vial or as a standard dose divided among several capped V-vials.
QuiremSpheres® is a product manufactured by Quirem Medical B.V. and has CE-mark.
QuiremSpheres® is not available for sale in all countries. This information is provided only in respect to markets where the product is approved or cleared. QuiremSpheres® is not FDA cleared in the US for sale.
QuiremSpheres® is not approved in Canada